Stayveer 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
WS/2404 
This was an application for a variation following a 
09/02/2023 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.f.1.d - Stability of FP - Change in storage 
conditions of the finished product or the 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
diluted/reconstituted product 
IG/1538 
A.4 - Administrative change - Change in the name 
08/08/2022 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
WS/2260 
This was an application for a variation following a 
07/07/2022 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
PSUSA/425/2
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
02111 
bosentan 
WS/2052/G 
This was an application for a group of variations 
10/06/2021 
07/06/2022 
SmPC, Annex 
The information regarding the clinical study of bosentan in 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
Grouped variation application; 
• 
Type II variation  C.I.4: Update of section 
4.6 of the SmPC to correct the information related to 
male fertility based on a review of study AC-052-402 
carried out by the MAH. 
• 
Type IA variation,  A.7: Deletion of a batch 
release site Actelion Manufacturing GmbH, Grenzach-
II and PL 
men with PAH (AC-052-402) has been updated regarding 
the proportion of subjects with a decreased sperm 
concentration of at least 50% from baseline after 6 months 
of treatment. 
For more information, please refer to the Summary of 
Product Characteristics. 
Page 2/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Wyhlen, Germany. 
In addition, the WSA took the opportunity to update 
the list of local representatives in the Package 
Leaflet.  The WSA also took the opportunity to 
correct some errors in the national translations. 
A.7 - Administrative change - Deletion of 
manufacturing sites 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
PSUSA/425/2
Periodic Safety Update EU Single assessment - 
10/06/2021 
n/a 
PRAC Recommendation - maintenance 
02011 
bosentan 
N/0032 
Minor change in labelling or package leaflet not 
23/09/2020 
07/06/2022 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
PSUSA/425/2
Periodic Safety Update EU Single assessment - 
11/06/2020 
n/a 
PRAC Recommendation - maintenance 
01911 
bosentan 
IAIN/0031/G 
This was an application for a group of variations. 
10/04/2020 
15/09/2020 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
Page 3/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0029 
B.I.b.1.b - Change in the specification parameters 
12/12/2019 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
II/0028 
Update of section 4.2 of the SmPC in order to include 
05/09/2019 
15/09/2020 
SmPC, Annex 
II, Labelling 
and PL 
that patients should be given the Package Leaflet 
and the Patient Alert Card which are included in the 
pack and update of annex II.D to remove the 
Prescriber kit from the additional risk minimisation 
measures and also to remove the obligation to 
implement a formal "Controlled Distribution System" 
in EU countries following the assessment of LEG 
10.2. The RMP version 11 has also been submitted. 
In addition, the Marketing authorisation holder 
(MAH) took the opportunity to update the contact 
details of the local representative in the UK, to bring 
the PI in line with the latest QRD template version 
10, and with the guideline on Excipients in the 
labelling and package leaflet of medicinal products 
for human use (EMA/CHMP/302620/2017), and to 
implement some corrections to the Bulgarian 
translations. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
II/0027 
Submission of the final report from study AC-052-
11/07/2019 
15/09/2020 
Annex II 
516 (a category 1 study). This is a non-interventional 
Page 4/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
observational study of the disease characteristics and 
outcomes of Pulmonary Arterial Hypertension in 
children and adolescents in real-world clinical 
settings. Annex IID is updated accordingly.  
An updated RMP version 10 has was agreed during 
the procedure. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
PSUSA/425/2
Periodic Safety Update EU Single assessment - 
14/06/2019 
n/a 
PRAC Recommendation - maintenance 
01811 
bosentan 
T/0025 
Transfer of Marketing Authorisation 
08/02/2019 
11/03/2019 
SmPC, 
Labelling and 
PL 
IA/0024/G 
This was an application for a group of variations. 
08/08/2018 
n/a 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
Page 5/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0023 
Update of Annex II.D and the RMP (version 9.2) 
12/07/2018 
11/03/2019 
SmPC, Annex 
following the submission of the final (13th) study 
II and PL 
report of the DUO Registry (a Category 3 non-
interventional post-approval safety study and 
additional risk minimisation measure in the bosentan 
European Risk Management Plan). The MAH took the 
opportunity to include some editorial changes in the 
SmPC and to update the list of local representatives 
in the PL. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
PSUSA/425/2
Periodic Safety Update EU Single assessment - 
14/06/2018 
n/a 
PRAC Recommendation - maintenance 
01711 
bosentan 
R/0021 
Renewal of the marketing authorisation. 
09/11/2017 
08/01/2018 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Stayveer in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
PSUSA/425/2
Periodic Safety Update EU Single assessment - 
20/07/2017 
26/09/2017 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
01611 
bosentan 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/425/201611. 
IB/0018/G 
This was an application for a group of variations. 
25/09/2017 
n/a 
Page 6/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.d.1.a.1 - Stability of AS - Change in the re-test 
period/storage period - Reduction 
B.I.d.1.b.3 - Stability of AS - Change in the storage 
conditions - Change in storage conditions of the AS 
IA/0020/G 
This was an application for a group of variations. 
04/08/2017 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.7 - Administrative change - Deletion of 
manufacturing sites 
IA/0019 
A.7 - Administrative change - Deletion of 
04/08/2017 
n/a 
manufacturing sites 
IB/0017 
C.I.z - Changes (Safety/Efficacy) of Human and 
21/05/2017 
26/09/2017 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
PSUSA/425/2
Periodic Safety Update EU Single assessment - 
21/07/2016 
22/09/2016 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
01511 
bosentan 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/425/201511. 
IB/0015/G 
This was an application for a group of variations. 
15/09/2016 
26/09/2017 
SmPC, 
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
Labelling and 
PL 
Page 7/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
IG/0665 
B.II.d.2.a - Change in test procedure for the finished 
10/03/2016 
n/a 
product - Minor changes to an approved test 
procedure 
WS/0899/G 
This was an application for a group of variations 
25/02/2016 
22/09/2016 
SmPC, Annex 
II, Labelling 
and PL 
following a worksharing procedure according to 
Article 20 of Commission Regulation (EC) No 
1234/2008. 
Submission of a revised RMP in order to align the 
additional risk minimisation measures of three safety 
concerns (`Pulmonary oedema associated with veno-
occlusive disease', `Interaction with sildenafil' and 
`Interaction with antiretrovirals'), with the 
requirements defined in Annex II of the Marketing 
Authorisation. The RMP is also being updated with 
the outcome of previous procedures and other 
corrections. In addition, Annex II has been modified 
to reflect that the submission cycle of interim reports 
of the paediatric registries should be 3-yearly. 
Furthermore, the MAH took the opportunity to align 
the product information with the latest QRD template 
version 9.1 and to update the list of local 
representatives in the package leaflet. 
C.I.11.b - Introduction of, or change(s) to, the 
Page 8/12 
 
 
 
 
 
 
 
 
 
 
 
 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/425/2
Periodic Safety Update EU Single assessment - 
25/06/2015 
20/08/2015 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
01411 
bosentan 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/425/201411. 
II/0011 
Update of SmPC sections 4.2, 4.5, 4.6, 4.8, 5.1, 5.2 
25/06/2015 
28/07/2015 
SmPC, Annex 
For further information, please refer to the scientific 
and 5.3 to reflect non-clinical and clinical data 
generated in studies conducted according to the 
agreed Paediatric Investigation Plan for bosentan 
(EMEA-000425-PIP02-10-M04) in line with 
application II-66 for Tracleer (bosentan) approved by 
CHMP in November 2014. The Annex II and the 
Package Leaflet have been updated accordingly. 
Further, the MAH took the opportunity to make 
editorial changes in the SmPC and to update the 
II and PL 
discussion ‘Stayveer-H-C-2644-II-11’. 
Page 9/12 
 
 
 
 
 
 
 
contact details of the local representatives in the 
Package Leaflet. In addition, taking into account the 
new data in the paediatric population, an updated 
version of the RMP (version 7) aligned with RMP 
version 7 for Tracleer was provided. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
N/0009 
Minor change in labelling or package leaflet not 
13/06/2014 
19/12/2014 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUV/0006 
Periodic Safety Update 
12/06/2014 
n/a 
PRAC Recommendation - maintenance 
IG/0441/G 
This was an application for a group of variations. 
23/05/2014 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0007/G 
This was an application for a group of variations. 
10/04/2014 
19/12/2014 
SmPC, 
Page 10/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
II/0003 
To replace sites responsible for manufacture of active 
20/02/2014 
n/a 
substance. 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IB/0005/G 
This was an application for a group of variations. 
09/02/2014 
19/12/2014 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.8.a - Introduction of or changes to a summary of 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
IAIN/0004 
B.II.b.2.c.2 - Change to importer, batch release 
08/01/2014 
19/12/2014 
Annex II and 
Page 11/12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
arrangements and quality control testing of the FP - 
PL 
Including batch control/testing 
IG/0352/G 
This was an application for a group of variations. 
05/09/2013 
n/a 
B.II.d.1.a - Change in the specification parameters 
and/or limits of the finished product - Tightening of 
specification limits 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
Page 12/12 
 
 
 
 
 
 
 
 
 
 
 
